Enicepatide vs Tirzepatide: Two GLP-1/GIP Dual Agonists Compared

Enicepatide and tirzepatide target the same two incretin receptors — GLP-1 and GIP — and are both once-weekly subcutaneous injections, which makes them the closest mechanistic comparison in the obesity pipeline. The decisive differences are development stage, the molecular signalling design, and how their reported weight-loss numbers were measured.

Receptor Pharmacology

Both drugs are dual GLP-1/GIP receptor agonists. Activation of the GLP-1 receptor slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses post-meal glucagon, and reduces appetite; co-activation of the GIP receptor is thought to add metabolic benefit and may improve gastrointestinal tolerability relative to GLP-1 alone. They are distinct molecules, not different brands of the same compound.

The design difference Roche emphasizes for enicepatide is biased signalling — the molecule is engineered for minimal-to-no beta-arrestin recruitment at both receptors. Beta-arrestin recruitment normally drives receptor internalization and desensitization, so limiting it is intended to sustain receptor activity over time. Whether that mechanistic distinction produces a clinical advantage over tirzepatide is unknown; no head-to-head trial exists.

Weight Loss Magnitude — and an Important Measurement Caveat

Enicepatide's Phase 2 CT388-103 trial, presented at ADA 2026, reported approximately 22.5% placebo-adjusted mean body weight reduction at 48 weeks. Tirzepatide's pivotal SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported approximately 20.9% absolute mean weight reduction at 72 weeks on the 15 mg dose, with the placebo arm losing roughly 2–3% — so the placebo-adjusted figure for tirzepatide is closer to ~18%.

This is the central caution: "placebo-adjusted" and "absolute" are not the same number, and comparing enicepatide's placebo-adjusted figure directly against tirzepatide's absolute figure overstates the difference. The two trials also differ in duration (48 vs 72 weeks), population, and dose tiers. What can be said fairly is that enicepatide's Phase 2 efficacy appears competitive with the established dual-agonist standard — but Phase 2 results commonly shift in Phase 3, and only a head-to-head trial could settle a ranking.

Regulatory Status

Tirzepatide is FDA-approved: Mounjaro (May 2022) for type 2 diabetes and Zepbound (November 2023) for chronic weight management. It has years of post-approval safety experience, established insurance pathways, and a cardiovascular outcomes evidence base. Enicepatide is investigational as of June 2026 — in Phase 2 with Phase 3 planned. It is not legally available outside of clinical trials and is not eligible for compounding.

Side Effect Profile

Both drugs share the incretin-class side-effect profile dominated by gastrointestinal events (nausea, vomiting, diarrhea, constipation), most pronounced during dose escalation. Tirzepatide's profile is well characterized across the large SURMOUNT and SURPASS programs; enicepatide's is characterized only through Phase 2, so its full tolerability and discontinuation picture awaits peer-reviewed publication and Phase 3 data. The GLP-1 class boxed warning for thyroid C-cell tumors (based on rodent data) is anticipated to apply to enicepatide by class-labeling precedent.

Cost and Access

Tirzepatide has a U.S. list price of roughly $1,000–$1,350 per month, with growing but variable obesity-indication coverage and manufacturer savings programs. Enicepatide has no established price because it is not commercially available; if approved, it would likely enter a similar premium tier. Access economics across the incretin class remain a significant barrier for most people who could clinically benefit.